Related Experiment Video

Updated: May 11, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Both carvedilol and nebivolol may improve platelet function and prothrombotic state in patients with nonischemic

Mustafa Karabacak1, Abdullah Dogan2, Fatih Aksoy3

  • 1Department of Cardiology, Isparta State Hospital, Isparta, Turkey drmustafa1979@hotmail.com.

Angiology
|May 15, 2013
PubMed

Insights

Carvedilol and nebivolol similarly improve platelet function and reduce prothrombotic state in heart failure (HF) patients. Both medications demonstrated comparable benefits, with carvedilol showing a slight trend towards greater reduction in mean platelet volume.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hematology

Background:

  • Heart failure (HF) involves altered platelet function and a prothrombotic state.
  • The comparative effects of carvedilol and nebivolol on these parameters in nonischemic HF are not well-defined.

Purpose of the Study:

  • To compare the effects of carvedilol versus nebivolol on platelet function and prothrombotic markers in patients with nonischemic heart failure.

Main Methods:

  • A randomized study involving 61 patients with symptomatic nonischemic HF (ejection fraction ≤40%).
  • Patients were assigned to receive either carvedilol (n=31) or nebivolol (n=30).
  • Platelet function markers, including mean platelet volume (MPV), fibrinogen, and d-dimer, were assessed at baseline, 3 months, and 6 months.

Main Results:

  • Both carvedilol and nebivolol significantly reduced MPV, fibrinogen, and d-dimer levels at 6 months.
  • MPV showed a trend towards a greater reduction in the carvedilol group (P = .05).
  • No significant differences in fibrinogen and d-dimer levels were observed between the two groups at 6 months.

Conclusions:

  • Carvedilol and nebivolol exhibit similar beneficial effects on platelet function and prothrombotic state in patients with nonischemic HF.
  • These findings suggest that both beta-blockers can positively modulate thrombotic risk factors in this patient population.

Keywords:
d-dimercarvedilolfibrinogenheart failuremean platelet volumenebivolol

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...